Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05259930
Other study ID # 21143A01
Secondary ID 21/93
Status Recruiting
Phase N/A
First received
Last updated
Start date March 2, 2022
Est. completion date August 2025

Study information

Verified date December 2023
Source Royal College of Surgeons, Ireland
Contact Ciara O'Connor
Phone 01 809 3880
Email ciaraaoconnor@rcsi.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Malnutrition and reduced muscle mass have been associated with poor outcomes in many disease conditions including severe inflammatory bowel disease, liver failure and cancers. Studies have shown that use of an amino acid supplement can specifically support muscle and nutritional health of patients with liver cirrhosis and malnutrition in general. The investigators will perform new novel non-invasive measurements of muscle mass and strength as well as inflammatory markers and record food diaries in the investigators patients with inflammatory bowel disease, cirrhosis of the liver and other gastroenterology disease impacting patient nutrition. The investigators hope to determine if of the addition of BCAA in addition to best practice nutrition supports for patients with cirrhosis will improve muscle mass and clinical outcomes in the investigators patient cohort including hospitalization, rate of decompensations, frailty score and quality of life for patients with liver cirrhosis. The investigators intend to investigate whether immune-metabolic profiles, circulating T-cells and circulating plasma cytokines (Afzal et al, J. Clin. Med. 2020) may act as biomarkers in combination with non-invasive novel markers of muscle mass in patients with chronic gastrointestinal illness, particularly cirrhosis to predict outcomes, and whether implementation of best practice nutritional supports with addition of Amino MP9 supplementation may impact functional outcomes. The immunometabolic profiles of these cohorts in relation to macrophage and T Cell function and differentiation have not been described previously. The investigators also hope to develop a system facilitating accurate assessments of nutritional status in gastroenterology patients and determine if there is correlation with objective clinical activity measured using endoscopy, faecal calprotectin or radiological evidence of inflammation, currently measured as part of standard practice. Sub-analysis will investigate potential association between longitudinal diet evaluation using EDIP (empirical dietary inflammatory pattern) score and disease activity, clinical remission and response to medical therapy, all influencing quality of life and patient related outcome measures. A prospective observational analysis of nutritional status and muscle mass or sarcopenia in patients attending gastroenterology services at Beaumont Hospital. Patients will be recruited from Gastroenterology and Hepatology outpatient clinics or inpatient capacity. Controls will be recruited from outpatient setting.


Description:

The investigators objectives are summarised as, Objective 1: The investigators review 25-30 new patients, and approximately 120 return patients across 4 weekly clinics. These include approximately 40 patients with chronic liver disease or cirrhosis. In order to test validity of non-invasive markers of muscle mass including BIA device and thigh ultrasound in specific patient populations, the investigators propose recruitment of 100 patients and 30 controls. Objective 2: The investigators propose recruitment of 50 patients with cirrhosis to receive nutrition support plus Amino MP9 (BCAA supplementation), 50 patients with cirrhosis to receive nutrition support alone and 30 controls. The following criteria are set for recruitment of patients into this study: Inclusion Criteria Confirmed cirrhosis (clinical or radiological diagnosis using liver biopsy, ultrasound/CT and/or transient elastography, Fibroscan) Age > 18 years Child Pugh score ≥B7 Active or recent (within the preceding 2 years) cirrhosis-related complication(s): including alcoholic hepatitis, ascites, variceal bleeding, spontaneous bacterial peritonitis, sepsis, encephalopathy, liver-related renal dysfunction, or hepatocellular carcinoma BCLC (Barcelona-Clinic Liver Cancer) stage A or B. Exclusion Criteria Active cancer (non-HCC) Advanced stage hepatocellular carcinoma (BCLC stage C or D) Pregnancy Breastfeeding/Lactation Lack of capacity for informed consent Hepatic Encephalopathy > Grade 2 at recruitment Listed for liver transplant Consumption of anabolic steroids for purpose of muscle development In this study patients will divided recruited patients into 3 different arms, as follows: Arm 1 (n=50): Patients with chronic liver disease and >F4 fibrosis on imaging (n=50) to receive best practice nutritional assessment and supports. Arm 2 (n=50): Patients with chronic liver disease and >F4 fibrosis on imaging, to receive best practice nutritional assessment and supports in addition to a 12-week course of daily Amino MP9, BCAA supplement Arm 3 (n=30): Controls attending gastroenterology outpatient or endoscopy services with no chronic inflammatory GI disease. The investigators measurable outcomes includes: Primary Outcome 1. Decompensation requiring hospital admission, surgery or medical intervention. 2. Improvement in anterior thigh muscle mass scores on ultrasound and non-invasive markers of muscle mass using SECA analysis Secondary Outcome 1. Mortality 2. Impact of BCAA supplementation on immunometabolic markers in cirrhosis 3. Improvement in frailty and quality of life Patients identified as suitable for recruitment will be invited to participate in this study which entails comprehensive nutritional assessment in addition to current standard medical practices and investigations {routine weight (in kg) and BMI(kg/m²)} at each hospital attendance. Patients with liver cirrhosis will be randomised 1:1 to receive either standard of care with nutrition assessment or nutrition assessment plus Amino MP9 supplementation. Patients in these groups and additionally, patients with chronic gastrointestinal diseases will undergo below assessments with regular dietetic analysis and review (currently not available due to resource limitations) to determine whether a prognostic score and cost benefit analysis of strict implementations of nutritional recommendations relates to prognosis. Completion at 0, 3, 12, 24 weeks. Additional nutrition assessment offered will include: 1. Food frequency questionnaires (FFQ) (subsequent calculation of EDIP score) 2. Mid abdominal circumference measurement 3. Hand-grip strength 4. Sit-to-stand timed test 5. Mid-thigh circumference measurement 6. Gait speed test 7. Bilateral anterior thigh muscle mass via ultrasound 8. Muscle mass and strength through BIA device 9. Balance assessment - quality of life score assessment through CLD-Q questionnaire - For cirrhotic cohort the investigators will monitor level of encephalopathy through trail and stroop tests. Immunometabolic Profile at at 0, 3, 12 and 24 weeks -> Plasma cytokine (IL 1, 6, 8, 10, 23, 17, TNF), myostatin, leptin, ghrelin and adiponectin analysis. Immunometabolic circulating T-cell and macrophage profile


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date August 2025
Est. primary completion date July 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed cirrhosis (clinical or radiological diagnosis using liver biopsy, ultrasound/CT and/or transient elastography, Fibroscan) - Age > 18 years - Child Pugh score =B7 - Active or recent (within the preceding 2 years) cirrhosis-related complication(s): including alcoholic hepatitis, ascites, variceal bleeding, spontaneous bacterial peritonitis, sepsis, encephalopathy, liver-related renal dysfunction, or hepatocellular carcinoma BCLC (Barcelona-Clinic Liver Cancer) stage A or B. Exclusion Criteria: - Active cancer (non-HCC) - Advanced stage hepatocellular carcinoma (BCLC stage C or D) - Pregnancy - Breastfeeding/Lactation - Lack of capacity for informed consent - Hepatic Encephalopathy > Grade 2 at recruitment - Listed for liver transplant - Consumption of anabolic steroids for purpose of muscle development

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Amino MP9
Name used by Nualtra for their product of BCAA

Locations

Country Name City State
Ireland Royal College of Surgeons in Ireland Dublin

Sponsors (2)

Lead Sponsor Collaborator
Royal College of Surgeons, Ireland Nualtra

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver decompensation requiring hospital admission Decompensated cirrhosis is defined as a patient with cirrhosis who presents with an acute deterioration in liver function that can manifest with the following symptoms:
hepatic encephalopathy (equal or greater than 2), sepsis, new ascites/increase ascites, clinical jaundice, acute kidney injury according to modified RIFLE criteria and signs of gastrointestinal bleeding including melaena, haematemesis or coffee-ground vomiting
3 months
Primary Liver decompensation requiring hospital admission Decompensated cirrhosis is defined as a patient with cirrhosis who presents with an acute deterioration in liver function that can manifest with the following symptoms:
hepatic encephalopathy (equal or greater than 2), sepsis, new ascites/increase ascites, clinical jaundice, acute kidney injury according to modified RIFLE criteria and signs of gastrointestinal bleeding including melaena, haematemesis or coffee-ground vomiting hepatic encephalopathy (equal or greater than 2), sepsis, new ascites/increase ascites, clinical jaundice , acute kidney injury according to modified RIFLE criteria and signs of gastrointestinal bleeding including melaena, haematemesis or coffee-ground vomiting
6 months
Primary Anterior thigh muscle mass thickness Improvement in anterior thigh muscle mass thickness on ultrasound (in millimetre) 3 months
Primary Anterior thigh muscle mass thickness Improvement in anterior thigh muscle mass thickness on ultrasound (in millimetre) 6 months
Primary Segmental muscle mass Improvement in segmental muscle mass analysis through Bio-impedance analysis device (SECA device). Muscle mass of arms, legs and trunk will be measured in kilogram. 3 months
Primary Segmental muscle mass Improvement in segmental muscle mass analysis through Bio-impedance analysis device (SECA device). Muscle mass of arms, legs and trunk will be measured in kilogram. 6 months
Secondary Mortality 6 months
Secondary Impact of BCAA supplementation on cytokines and immunometabolic markers in cirrhosis Impact of BCAA on immune system this included measurements of (IL 1, 6, 8, 10, 23, 17, TNF), myostatin, leptin, ghrelin and adiponectin analysis. These will be measured with flow cytometry. Immunometabolic circulating T-cell and macrophage profile with flow cytometry. Measurements will be calculated with pg/mL scale. 3 months
Secondary Impact of BCAA supplementation on cytokines and immunometabolic markers in cirrhosis Impact of BCAA on immune system this included measurements of (IL 1, 6, 8, 10, 23, 17, TNF), myostatin, leptin, ghrelin and adiponectin analysis. These will be measured with flow cytometry. Immunometabolic circulating T-cell and macrophage profile with flow cytometry. Measurements will be calculated with pg/mL scale. 6 months
Secondary Improvement in frailty Improvement in frailty of liver cirrhotic patient and their quality of life based on liver frailty index { (-0.330 × gender - adjusted grip strength in kilogram) + (-2.529 × number of chair stands per seconds) + (-0.040 × balance time in second) + 6 } 3 months
Secondary Improvement in frailty Improvement in frailty of liver cirrhotic patient and their quality of life based on liver frailty index { (-0.330 × gender - adjusted grip strength in kilogram) + (-2.529 × number of chair stands per seconds) + (-0.040 × balance time in second) + 6 } 6 months
Secondary Improvement in quality of life Quality of life will be assessed with validated questionnaire, CLD-Q. This is consistent of 29 questions and it will assess patient's quality of life 2 weeks prior to assessments. 3 months
Secondary Improvement in quality of life Quality of life will be assessed with validated questionnaire, CLD-Q. This is consistent of 29 questions and it will assess patient's quality of life 2 weeks prior to assessments. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Recruiting NCT05063279 - RELIEF - Resistance Training for Life N/A
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Recruiting NCT06143592 - Inspiratory Muscle Training on Balance, Falls and Diaphragm Thickness in the Elderly N/A
Terminated NCT04350762 - Nutritional Supplementation in the Elderly With Weight Loss N/A
Enrolling by invitation NCT05953116 - Managing the Nutritional Needs of Older Filipino With Due Attention to Protein Nutrition and Functional Health Study N/A
Recruiting NCT04028206 - Resistance Exercise or Vibration With HMB for Sarcopenia N/A
Enrolling by invitation NCT03297632 - Improving Muscle Strength, Mass and Physical Function in Older Adults N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A
Completed NCT03234920 - Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation N/A
Recruiting NCT03998202 - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Recruiting NCT04717869 - Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
Completed NCT05497687 - Strength-building Lifestyle-integrated Intervention N/A
Completed NCT03119610 - The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity Phase 1/Phase 2
Recruiting NCT05711095 - The Anabolic Properties of Fortified Plant-based Protein in Older People N/A
Recruiting NCT05008770 - Trial in Elderly With Musculoskeletal Problems Due to Underlying Sarcopenia - Faeces to Unravel Gut and Inflammation Translationally
Not yet recruiting NCT05860556 - Sustainable Eating Pattern to Limit Malnutrition in Older Adults
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease